Data from the TORO clinical trials demonstrate a statistically significant increase in CD4 cells in treatment-experienced patients with FUZEON-based regimens as compared to regimens without FUZEON.^1-3



In RESIST trials, regimens with FUZEON plus boosted tipranavir provided a mean CD4 increase of 88 cells/mm³ at 48 weeks (LOCF) in triple-class-experienced patients with documented resistance to PIs. Regimens without FUZEON provided a mean increase of 32 CD4 cells/mm³.

Click here to read the full Prescribing Information for FUZEON.

Click here to read the Important Safety Information.

1. Miralles GD, DeMasi R. Virologic suppression of an active boosted-PI regimen is significantly enhanced by the addition of a fusion inhibitor in treatment-experienced patients. Program and abstracts from the 42nd Annual Meeting of IDSA. September 30-October 3, 2004; Boston, MA. Poster 921.
2. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr. 2005;40(4):404-412.
3. Trottier B, Walmsley S, Reynes J, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr. 2005;40(4):413-421.
4. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimized background regimen of antiretroviral drugs for treatment of HIV-1 infected patients at 48 weeks (RESIST): an analysis of combined data from two randomized open label trials. Lancet. 2006;368(9534):466-475.